Zelda Therapeutics on rapid path to medicinal cannabis commercialisation

Zelda Therapeutics Ltd (ASX:ZLD) is on a rapid path to commercialisation of its medicinal cannabis products aimed at treating pain, anxiety, sleep apnea and cancer.

The company’s managing director Dr Richard Hopkins told investors at this week’s Proactive CEO Sessions in Sydney and Melbourne that the company is well placed to service a rapidly growing global market.

READ: Zelda Therapeutics to use Federal Government RD tax rebate of $769,000 to drive clinical trials

He said the company was building a portfolio of clinically validated assets which presented multiple revenue opportunities to license and generate milestone and royalty payments.

This strategy was well advanced because the company had a singular focus on clinical validation to address key unmet needs.

Market dynamics

Among the interesting medicinal cannabis market dynamics outlined were: